GlassScriptPhysician profile
Shane M Pahlavan
NPI 1124271689
$94,534.64
in general payments reported to CMS, 2019-2025
24 companies · $14K in 2025
The $14K reported for 2025 was more than what 97% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $211 · 2021: $1,631 · 2022: $24K · 2023: $20K · 2024: $33K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $7,248 · Food and Beverage: $5,394 · Honoraria: $2,000 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,787.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,384.24 |
| Travel and Lodging | $7,248.46 |
| Food and Beverage | $5,394.42 |
| Honoraria | $2,000.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19,570.42 | 2023-2025 | Propel, Nuvent |
| Olympus America INC. | $18,383.55 | 2020-2024 | Olympus, Rhino-Laryngo Videoscope |
| Acclarent, INC | $18,170.58 | 2019-2024 | Trudi Nav Cable, Acclarent Aera, Relieva Spinplus |
| Inspire Medical Systems, INC. | $15,862.90 | 2019-2025 | Inspire |
| Medical Device Business Services, INC. | $9,000.00 | 2022-2023 | |
| Aerin Medical INC. | $6,301.34 | 2019-2024 | |
| Integra Lifesciences Corporation | $3,622.18 | 2024-2025 | Acclarent Aera, Trudi Probe, Inspira Air |
| Livanova USA, INC. | $878.15 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Thn Sleep Therapy |
| Gyrus Acmi, INC. | $690.00 | 2022 | |
| Neurent Medical Limited | $587.71 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Genzyme Corporation | $453.36 | 2024-2025 | |
| Stryker Corporation | $357.20 | 2019-2022 | |
| Intersect Ent, INC. | $162.54 | 2019-2022 | |
| Olympus Corporation of The Americas | $108.31 | 2023 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microtransponder, INC. | $61.55 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $47.89 | 2023 | Dupixent |
| Glaxosmithkline, LLC. | $46.60 | 2023-2025 | Nucala |
| Amgen INC. | $39.50 | 2025 | Tezspire |
| Cochlear Americas | $21.89 | 2019 | |
| Lilly USA, LLC | $19.73 | 2025 | Zepbound |
| Optinose US, INC. | $17.82 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $16.06 | 2025 | Tezspire |
| Arbor Pharmaceuticals, INC. | $15.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Pahlavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.